Back

Autocrine Proteinase Activated Receptor (PAR) mediated signaling in prostate cancer cells.

Chandrabalan, A.; Ramachandran, R.

2022-08-22 cancer biology
10.1101/2022.08.22.504840 bioRxiv
Show abstract

Proteinase activated receptors (PARs) are G protein-coupled receptors (GPCRs) activated by limited N-terminal proteolysis. A variety of proteolytic enzymes derived from the coagulation cascade and inflammatory milieu activate PARs, however specific activators in different physiological and pathophysiological contexts remain poorly defined. PARs are highly expressed in many cancer cells and regulate various aspects of tumor growth and metastasis. Endogenous proteinases that regulate PARs in the setting of various tumors however remains unresolved. Prostate cancer (PCa) remains a major cause of mortality in men despite advances in early detection and clinical intervention. PAR expression has been reported in PCa, however, their role here remains poorly defined. In androgen independent PC3 cells, we find functional expression of PAR1 and PAR2 but not PAR4. Using genetically encoded PAR cleavage biosensors, we find that PCa cells secrete proteolytic enzymes that cleave PARs and trigger autocrine signaling. Deletion of PAR1 and PAR2 using CRISPR/Cas9 combined with microarray analysis revealed genes that are differentially regulated by this autocrine signalling mechanism. Interestingly, several genes that are known PCa prognostic factors or biomarker were differentially expressed in PAR1-KO and PAR2-KO PC3 cells. We also examined PAR1 and PAR2 regulation of PCa cell proliferation and migration using PAR1 and PAR2-KO PC3 cells, as well as PAR1 and PAR2 specific agonists and antagonists. We find that PAR1 and PAR2 have opposite effects on PC3 cell proliferation and migration. In summary, we have identified an autocrine signaling mechanism through PARs as a regulator of PCa cell function.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3612 papers in training set
Top 3%
12.1%
2
PLOS ONE
5266 papers in training set
Top 18%
9.9%
3
Cellular Signalling
14 papers in training set
Top 0.1%
8.0%
4
Cells
249 papers in training set
Top 0.3%
5.2%
5
Journal of Biological Chemistry
690 papers in training set
Top 2%
4.9%
6
eLife
5828 papers in training set
Top 33%
3.3%
7
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.2%
2.8%
8
Cell Communication and Signaling
51 papers in training set
Top 0.2%
2.8%
9
Biochemical Pharmacology
20 papers in training set
Top 0.1%
2.2%
50% of probability mass above
10
Bioscience Reports
27 papers in training set
Top 0.5%
2.2%
11
Oncogene
85 papers in training set
Top 0.8%
2.2%
12
International Journal of Molecular Sciences
494 papers in training set
Top 7%
1.9%
13
Cell Death Discovery
58 papers in training set
Top 0.5%
1.8%
14
Oncotarget
18 papers in training set
Top 0.1%
1.8%
15
Neoplasia
23 papers in training set
Top 0.3%
1.8%
16
Communications Biology
993 papers in training set
Top 18%
1.4%
17
Frontiers in Oncology
103 papers in training set
Top 2%
1.4%
18
The FASEB Journal
194 papers in training set
Top 4%
1.1%
19
Molecular Cancer Research
49 papers in training set
Top 0.9%
1.1%
20
Pharmaceuticals
34 papers in training set
Top 0.7%
1.1%
21
Oncogenesis
12 papers in training set
Top 0.2%
1.1%
22
Cell Death & Disease
126 papers in training set
Top 2%
1.1%
23
Journal of Cell Science
393 papers in training set
Top 3%
1.1%
24
The FEBS Journal
93 papers in training set
Top 2%
0.9%
25
iScience
1154 papers in training set
Top 33%
0.9%
26
Molecular Pharmacology
17 papers in training set
Top 0.2%
0.9%
27
Cancers
213 papers in training set
Top 5%
0.9%
28
Life Science Alliance
285 papers in training set
Top 7%
0.9%
29
European Journal of Cell Biology
15 papers in training set
Top 0.2%
0.9%
30
Frontiers in Pharmacology
111 papers in training set
Top 3%
0.6%